High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #
Keith D. Lindor(University of Padua), Felicity Enders(Mayo Clinic), Jill C. Keach(Mayo Clinic), Velimir A. Luketic(University of Padua), Timothy M. McCashland(University of Nebraska–Lincoln), Alex S. Befeler(Saint Louis University Hospital), Carol Sargeant(Virginia Commonwealth University), Jeff Schmoll(Mayo Clinic), Ellen Miceli(Jacksonville College), Denise M. Harnois(Jacksonville College), Prabin Thapa(Mayo Clinic), Jody Mooney(Virginia Mason Medical Center), Kris V. Kowdley(Washington State University Spokane), Roberta A. Jorgensen(Mayo Clinic), Tamara Bernard(University of Nebraska–Lincoln), Edwyn M Harrison(Mayo Clinic in Arizona), Jan Petz(Mayo Clinic), Julie K. Braaten, Debra King(Saint Louis University Hospital), Tanya L. Hoskin(Mayo Clinic)
Cited by 721
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k